secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001493152-24-039269
Event type: other
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers
--------------------------------------------------------------------------------

- Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.
- Proceeds for working capital and general corporate purposes; closing expected October 4, 2024.
- Two leading transplant university hospitals in U.S. and Germany adopt GraftAssure research assay for graft damage monitoring.
- Submitted Q-Sub to FDA for IVD version of dd-cfDNA test; FDA meeting scheduled for early December 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224039269/0001493152-24-039269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224039269/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer